Incyte Corp. [INCY] stock is trading at $52.94, up 1.71%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INCY shares have gain 2.32% over the last week, with a monthly amount drifted -5.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Buy rating on February 23, 2024, and set its price target to $81. On February 14, 2024, downgrade downgraded it’s rating to Mkt Perform. Leerink Partners upgraded its rating to a Outperform but stick to its price target of $78 on December 13, 2023. Guggenheim upgraded its rating to a Buy but $86 remained the price target by the analyst firm on December 04, 2023. Goldman downgraded its rating to Neutral for this stock on November 21, 2023, and downed its price target to $65. In a note dated July 25, 2023, Citigroup initiated an Buy rating and provided a target price of $82 on this stock.
Incyte Corp. [INCY] stock has fluctuated between $50.27 and $75.74 over the past year. Currently, Wall Street analysts expect the stock to reach $85.64 within the next 12 months. Incyte Corp. [NASDAQ: INCY] shares were valued at $52.94 at the most recent close of the market. An investor can expect a potential return of 61.77% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Incyte Corp. [NASDAQ:INCY] reported sales of 3.77B for the trailing twelve months, which represents a growth of 8.93%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.15 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.80 points at the first support level, and at 50.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.03, and for the 2nd resistance point, it is at 55.12.
Ratios To Look Out For
For context, Incyte Corp.’s Current Ratio is 3.47. Also, the Quick Ratio is 3.43, while the Cash Ratio stands at 2.4. Considering the valuation of this stock, the price to sales ratio is 3.15, the price to book ratio is 2.20 and price to earnings (TTM) ratio is 16.07.
Transactions by insiders
Recent insider trading involved Stein Steven H, EVP & Chief Medical Officer, that happened on Jan 03 ’24 when 7365.0 shares were sold. EVP, GMAPPS, Iyengar Vijay K completed a deal on Jan 02 ’24 to sell 657.0 shares. Meanwhile, Principal Accounting Officer Tray Thomas sold 1067.0 shares on Dec 13 ’23.
